Phase I dose-escalation study of ALN-VSP02, a novel RNAi therapeutic for solid tumors with liver involvement.
A. Cervantes
No relevant relationships to disclose
M. Alsina
No relevant relationships to disclose
J. Tabernero
No relevant relationships to disclose
J. R. Infante
No relevant relationships to disclose
P. LoRusso
No relevant relationships to disclose
G. Shapiro
No relevant relationships to disclose
L. G. Paz-Ares
No relevant relationships to disclose
R. Falzone
Employment or Leadership Position - Alnylam
Stock Ownership - Alnylam
J. Hill
Employment or Leadership Position - Alnylam
Stock Ownership - Alnylam
J. Cehelsky
Employment or Leadership Position - Alnylam
Stock Ownership - Alnylam
A. White
Employment or Leadership Position - Alnylam
Stock Ownership - Alnylam
I. Toudjarska
Employment or Leadership Position - Alnylam
Stock Ownership - Alnylam
D. Bumcrot
Employment or Leadership Position - Alnylam
Stock Ownership - Alnylam
R. Meyers
Employment or Leadership Position - Alnylam
Stock Ownership - Alnylam
G. Hinkle
Employment or Leadership Position - Alnylam
Stock Ownership - Alnylam
N. Svrzikapa
Employment or Leadership Position - Alnylam
Stock Ownership - Alnylam
D. W. Sah
Employment or Leadership Position - Alnylam
Stock Ownership - Alnylam
A. Vaishnaw
Employment or Leadership Position - Alnylam
Stock Ownership - Alnylam
J. Gollob
Employment or Leadership Position - Alnylam
Stock Ownership - Alnylam
H. A. Burris
No relevant relationships to disclose